Healthcare Specialist

Winnie Wong

Equity Bottom-Up

<p>Blood product giant <a href="https://www.smartkarma.com/entities/917" target="_blank" data-smartkarma-citation="entities:917:1">CSL Ltd (CSL AU)</a> announced during its annual research &amp; development briefing this morning that it will proceed with a Phase 3 clinical trial for CSL112 (apolipoprotein A-I), which is the company's novel therapy for heart attack survivors.</p><p>The proposed Phase 3 clinical trial for CSL112 will be the largest study ever undertaken by CSL.  The study will recruit 17,400 patients (half with CSL1120 and half with placebo) from around 1,000 sites in over 40 countries.  The purpose of…</p>

Blood product giant CSL Ltd (CSL AU) announced during its annual research &amp; development briefing this morning that it will proceed with a Phase 3 clinical trial for CSL112 (apolipoprotein A-I), which is the company's novel therapy for heart attack survivors.The proposed Phase 3 clinical trial for CSL112 will be the largest study ever undertaken by CSL.  The study will recruit 17,400 patients (half with CSL1120 and half with placebo) from around 1,000 sites in over 40 countries.  The purpose of…

CSL's Largest-Ever Clinical Trial for Recurrent Heart Attacks: High Unmet Medical Need